Form 4: Edgewell Director Swan Sit Receives Stock Award

Edgewell Personal Care Company director Swan Sit acquired 7,817 restricted stock equivalents, aligning interests with shareholders.

Summary

• Director Swan Sit of Edgewell Personal Care Company (EPC) acquired 7,817 Restricted Stock Equivalents.
• The transaction occurred on February 5, 2026, and was reported on February 6, 2026.
• These restricted stock equivalents convert into shares of Edgewell common stock on the day preceding the next annual meeting of shareholders.
• The reporting person has the option to defer conversion until the termination of service on Edgewell's Board of Directors.
• The acquisition was made at a price of $0, indicating it was likely a grant or award.
• Following this transaction, Swan Sit beneficially owns 7,817 derivative securities (Restricted Stock Equivalents).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, as it represents a standard compensation practice that enhances director alignment with shareholder interests, without indicating any immediate operational or financial changes.

Positives

• The acquisition of restricted stock equivalents by a director aligns their interests with those of long-term shareholders, incentivizing performance and commitment.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged and systematic approach to equity compensation.

Risks

• The value of the restricted stock equivalents is tied to the future performance of Edgewell's common stock, meaning a decline in stock price would reduce the value of the award.
• The restricted nature of the award means the shares are not immediately liquid and are subject to vesting conditions (service until conversion).

Future Outlook

The filing indicates that Restricted Stock Equivalents will convert into common stock on the day preceding the next annual meeting of shareholders, or upon termination of service if deferred.

Industry Context

StockSavvy.ai notes that director stock awards, such as restricted stock equivalents, are a common form of compensation across various industries, including consumer goods. This practice aims to align the interests of board members with the long-term strategic goals and shareholder value creation of the company.

Comparison to Industry Standards

• StockSavvy.ai observes that granting restricted stock equivalents to directors is a standard practice across various industries, including consumer personal care, to incentivize long-term commitment and performance.
• Companies like Procter & Gamble (PG) and Kimberly-Clark (KMB) also utilize equity-based compensation for their board members, often tied to service or performance milestones, though specific grant sizes vary based on company size and compensation philosophy. This award to Director Sit is consistent with typical non-executive director compensation structures.

Corporate Governance

Related Party Transactions

• The acquisition of restricted stock equivalents by Director Swan Sit is a related party transaction, representing a standard form of equity compensation for board members.

Stakeholder Impact

• Shareholders: Potentially positive due to increased alignment of director interests with long-term company performance.
• Employees: No direct impact mentioned in this filing.

Next Steps

• Conversion of the 7,817 Restricted Stock Equivalents into shares of Edgewell common stock on the day preceding the next annual meeting of shareholders, unless deferred.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation award to a director, which is a standard corporate governance practice. While it signals alignment of interests, it does not present new information that would significantly alter the company's fundamental outlook or warrant an immediate change in investment posture. Therefore, a 'hold' recommendation is appropriate for seasoned investors.

Keywords

Edgewell Personal Care, EPC, Swan Sit, Director, Restricted Stock Equivalents, Insider Transaction, Form 4, Equity Compensation, Corporate Governance